Department of Medical Chemistry, Medical University of Gdansk, 80-211 Gdansk, Poland.
Euro-Mediterranean Institute of Science and Technology, 90127 Palermo, Italy.
Int J Mol Sci. 2020 Jan 17;21(2):616. doi: 10.3390/ijms21020616.
2-Methoxyestradiol is one of the natural 17β-estradiol derivatives and a potential novel anticancer agent currently being under evaluation in advanced phases of clinical trials. However, the mechanism of anticancer action of 2-methoxyestradiol has not been yet fully established. In our previous studies we have demonstrated that 2-methoxyestradiol selectively induces the expression and nuclear translocation of neuronal nitric oxide synthase in osteosarcoma 143B cells. Heat shock proteins (Hsps) are factors involved in the regulation of expression and activity of nitric oxide synthases. Herein, we chose osteosarcoma cell lines differed in metastatic potential, metastatic 143B and highly metastatic MG63.2 cells, in order to further investigate the anticancer mechanism of 2-methoxyestradiol. The current study aimed to determine the role of major heat shock proteins, Hsp90 and Hsp70 in 2-methoxyestradiol-induced osteosarcoma cell death. We focused on the implication of Hsp90 and Hsp70 in control under expression of neuronal nitric oxide synthase, localization of the enzyme, and further generation of nitro-oxidative stress. To give the insight into the role of Hsp90 in regulation of anticancer efficacy of 2-methoxyestradiol, we used geldanamycin as a potent Hsp90 inhibitor. Herein, we evidenced that inhibition of Hsp90 controls the protein expression of 2-methoxyestradiol-induced neuronal nitric oxide synthase and inhibits enzyme nuclear translocation. We propose that decreased level of neuronal nitric oxide synthase protein after a combined treatment with 2-methoxyestradiol and geldanamycin is directly associated with the accompanying upregulation of Hsp70 and downregulation of Hsp90. This interaction resulted in abrogation of anticancer efficacy of 2-methoxyestradiol by geldanamycin.
2-甲氧基雌二醇是 17β-雌二醇的天然衍生物之一,也是目前正在临床试验后期评估的一种有潜力的新型抗癌药物。然而,2-甲氧基雌二醇的抗癌作用机制尚未完全确定。在我们之前的研究中,我们已经证明 2-甲氧基雌二醇选择性诱导骨肉瘤 143B 细胞中神经元型一氧化氮合酶的表达和核转位。热休克蛋白(Hsps)是参与调节一氧化氮合酶表达和活性的因素。在此,我们选择了转移潜能不同的骨肉瘤细胞系,转移性 143B 和高转移性 MG63.2 细胞,以进一步研究 2-甲氧基雌二醇的抗癌机制。本研究旨在确定主要热休克蛋白 Hsp90 和 Hsp70 在 2-甲氧基雌二醇诱导骨肉瘤细胞死亡中的作用。我们专注于 Hsp90 和 Hsp70 在控制神经元型一氧化氮合酶表达、酶定位以及进一步产生硝基氧化应激中的作用。为了深入了解 Hsp90 在调节 2-甲氧基雌二醇抗癌疗效中的作用,我们使用格尔德霉素作为一种有效的 Hsp90 抑制剂。在此,我们证明抑制 Hsp90 控制 2-甲氧基雌二醇诱导的神经元型一氧化氮合酶的蛋白表达,并抑制酶的核转位。我们提出,在 2-甲氧基雌二醇和格尔德霉素联合治疗后,神经元型一氧化氮合酶蛋白水平降低与伴随的 Hsp70 上调和 Hsp90 下调直接相关。这种相互作用导致格尔德霉素对 2-甲氧基雌二醇抗癌疗效的阻断。